Baird analyst Eric Coldwell raised the firm’s price target on Medpace to $260 from $240 and keeps a Neutral rating on the shares. The firm noted the company beat/raised throughout, delivering a back-back enthusiastic environmental review.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MEDP:
